



Express Mail Label No. EV 010522372 US

Atty. Docket No. 5007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS:	SERIAL NO:	FILING DATE	ART UNIT:	CONFRM NO.
Calias, and Miller	09/784,402	February 15, 2001	1651	2991
TITLE:			EXAMINER:	
Modification of Biopolymers for improved Drug Delivery			Naff, David M	

#11  
H.G.J  
9/5/02

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

SEP 03 2002

Sir:

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

This Supplemental Information Disclosure Statement herewith is being filed before the mailing of a first Office Action on the merits.

Applicants submit form PTO-1449 for consideration under CFR § 1.97(b) along with copies of the references listed #1-10.

Applicants believe that no fee is due with this submission.

However, if any additional fees are required, the Commissioner is authorized to charge the said fees to Deposit Account No. 07-1074.

Respectfully submitted,

Isabelle A. S. Blundell, Ph.D.  
Attorney for the Applicants  
Reg. No. 43,321

Date: August 28, 2002  
Genzyme Corporation  
One Kendall Square  
Cambridge, MA 02139-1562  
Tel. No.: (617) 591-5698  
Fax No.: (617) 768-9558  
isabelle.blundell@genzyme.com